The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Decline in Research by Univ. Hospital Doctors Presents “Alarming Situation”: MEXT Official
October 10, 2011
- HPV Vaccines Competing for Public Subsidies; Are Parents Avoiding Vaccination by OB/GYN Doctors?
October 10, 2011
- MHLW to Set Up New System to Support Ultra-Orphan Drug Development
October 7, 2011
- Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
- MHLW Issues GL for Clinical Evaluation for Renal Anemia Drugs
October 5, 2011
- PMDA Invites Opinions on Candidate Drugs for JP Listing
October 5, 2011
- MHLW to Adopt Self-Evaluation by Generic Drug Makers for Stable Supply
October 5, 2011
- Korosho to Support Pharmacies’ Participation in Home Healthcare
October 5, 2011
- FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions
October 4, 2011
- MHLW Intends to Improve Self-sufficiency Ratio in HBIG Preparation
October 4, 2011
- Partial Change in Approval Is Not Necessary for 14 Products Including Allegra: PFSB
October 4, 2011
- Bill for Healthcare Reform for Elderly to Be Submitted to 2012 Diet: Health Minister
October 4, 2011
- METI Budget Request Includes ¥3.3 Bil. to Promote “Healthcare Industry Creation”
October 3, 2011
- Mr Akagawa of ELD Stresses Need for Closer East Asian Cooperation to Promote Multinational Trials
October 3, 2011
- Health Insurance Committee Unable to Agree on Proposed Fixed-sum Examination Fee
October 3, 2011
- Obama Administration’s Deficit-reduction Plan Calls For Shorter Exclusivity Period for Biologics
October 3, 2011
- Nat’l Medical Expenditure Rose 3.4% to Record ¥36,006.7 Billion in FY2009: MHLW
September 30, 2011
- MHLW Drug Subcommittee Withholds Approval of Additional Indication for Epogin
September 30, 2011
- MHLW to Request Perpetuation of “Add-on Credits,” “Credits for High-level R&D Investment”
September 29, 2011
- MHLW to Request Budget of ¥29,588.2 Bil., Special Framework Budget of ¥105.9 Bil. for FY2012
September 29, 2011
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…